Beta Drugs Ltd
📡AI Radar📊 Stock Analysis
Market Data
Face Value₹10
Performance
ROCE19.19 %
ROE18.63 %
EPS (TTM)₹14.78
EPS Prev Qtr₹8.93
EPS Last Year₹12.1
EBITDA Qtr₹23.02 Cr.
Financial Health
Debt/Equity0.6
Debt/Profit3.19
Total Assets₹495.8 Cr.
Promoter Holding59.1 %
Earning Power13.23 %
Valuation
Industry P/E33.3
Key Metrics
Face Value
₹10
About Beta Drugs Ltd
Healthcare · Pharmaceuticals
Beta Drugs Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹10.
Strengths & Weaknesses
Strengths
- The company demonstrates strong return metrics with a ROCE of 22.84% and ROE of 23.48%, indicating efficient use of capital and strong profitability.
- The promoter holding stands at 59.1%, suggesting significant control and potential alignment of interests with shareholders.
Weaknesses
- The company has a debt-to-equity ratio of 0.67, indicating a moderate level of financial leverage which could pose risks in volatile market conditions.
- With a net profit of ₹46.28 Cr on revenue of ₹410.17 Cr, the net profit margin appears relatively low, suggesting potential challenges in maintaining profitability.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.9 | ₹4,46,276.3 Cr | 0.86% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 85.97 | ₹2,51,531.48 Cr | 0.32% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 78.4 | ₹1,86,956.51 Cr | 0.77% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 26.64 | ₹1,19,221.66 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.13 | ₹1,11,725.01 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 98.01 | ₹1,07,271.96 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Mankind Pharma Ltd | - | 51.42 | ₹1,05,107.48 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Dr Reddys Laboratories Ltd | - | 32.31 | ₹1,04,334.48 Cr | 0.64% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Aurobindo Pharma Ltd | - | 26.61 | ₹97,986.86 Cr | 0.23% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.63 | ₹94,189.9 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 37.59 | ₹67,587.09 Cr | 0.1% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 29.02 | ₹62,609.02 Cr | 1.01% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 111.18 | ₹61,602.44 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.88 | ₹57,939.73 Cr | 1.74% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Gland Pharma Ltd | - | 43.62 | ₹49,299.85 Cr | 0.67% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ipca Laboratories Ltd | - | 36.55 | ₹49,280.78 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 85 | ₹49,084.9 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 44.95 | ₹47,217.7 Cr | 2.05% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ajanta Pharma Ltd | - | 39.17 | ₹44,452.1 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Sales | 103.39 | 87.27 | 93.96 | 125.55 |
| ↳ QoQ Growth | - | -15.6% | +7.7% | +33.6% |
| Expenses | 86.32 | 74.67 | 81.08 | 102.53 |
| Operating Profit | 17.07 | 12.6 | 12.88 | 23.02 |
| OPM % | 16.51% | 14.44% | 13.71% | 18.34% |
| Other Income | 2.99 | 2.31 | 2.89 | 1.58 |
| Interest | 3.61 | 4.43 | 3.94 | 2.56 |
| Depreciation | 4.24 | 4.39 | 4.8 | 4.35 |
| EBITDA | 21.31 | 16.99 | 17.68 | 27.37 |
| EBITDA Margin % | 20.61% | 19.47% | 18.82% | 21.8% |
| Profit Before Tax | 16.44 | 10.47 | 11.83 | 22.04 |
| Tax % | 25.73% | 18.62% | 23.5% | 25.23% |
| Net Profit | 12.22 | 8.52 | 9.05 | 16.49 |
| ↳ QoQ Growth | - | -30.3% | +6.2% | +82.2% |
| EPS | 12.1 | 8.4 | 8.93 | 14.78 |
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 10.094553 | 10.14 |
| Reserves | 187.00122 | 234.63 |
| Borrowings | 132.71 | 147.8 |
| Other Liabilities | 106.43 | 103.23 |
| Total Liabilities | 436.23465 | 495.8 |
| Fixed Assets | 88.93491 | 115.37 |
| CWIP | 0 | 0 |
| Investments | 0 | 0 |
| Other Assets | 347.3 | 380.43 |
| Total Assets | 436.23465 | 495.8 |
Cash Flows
| Mar 2025 | |
|---|---|
| Cash from Operating Activity | 36.144173 |
| Cash from Investing Activity | -35.718224 |
| Cash from Financing Activity | 117.965385 |
| Net Cash Flow | 118.39134 |
Shareholding Pattern
| Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|
| Promoters % | 64.9% | 66.73% | 59.1% |
| FIIs % | 1.14% | 0.9% | 1.02% |
| DIIs % | 1.9% | 0.29% | 6.23% |
| Public % | 21.78% | 21.81% | 24.3% |
| No. of Shareholders | 3,694 | 3,184 | 7,359 |
Major Shareholders (>1%)
- Neeraj BatraPromoter and Promoter Group58.40%
- Suryavanshi Commotrade Private LimitedPublic Shareholding6.13%
- Ashish KacholiaPublic Shareholding4.91%
- Healthquad Trust IiPublic Shareholding4.09%
As of 2026-06-30View all shareholders →